HS-438 is a potent and selective BCR-ABL inhibitor with antiproliferative and antitumor activities; it reduces the expression of phosphorylated BCR-ABL (Tyr177), induces apoptosis, and causes cell cycle arrest at the G0/G1 phase; it has potential for research in chronic myeloid leukemia (CML).